• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reinforcing the social compromise of accelerated approval.

作者信息

Gyawali Bishal, Kesselheim Aaron S

机构信息

Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

出版信息

Nat Rev Clin Oncol. 2018 Oct;15(10):596-597. doi: 10.1038/s41571-018-0066-3.

DOI:10.1038/s41571-018-0066-3
PMID:29970919
Abstract
摘要

相似文献

1
Reinforcing the social compromise of accelerated approval.加强加速批准的社会妥协。
Nat Rev Clin Oncol. 2018 Oct;15(10):596-597. doi: 10.1038/s41571-018-0066-3.
2
Does $760 m a year of industry funding affect the FDA's drug approval process?每年760万美元的行业资金会影响美国食品药品监督管理局（FDA）的药物审批程序吗？
BMJ. 2014 Aug 5;349:g5012. doi: 10.1136/bmj.g5012.
3
Reevaluating the accelerated approval process for oncology drugs.重新评估肿瘤药物的加速审批程序。
Clin Cancer Res. 2013 Jun 1;19(11):2804-9. doi: 10.1158/1078-0432.CCR-13-0315. Epub 2013 Apr 3.
4
Oncology pharmaceutical funding in New Zealand: a different approach and a proposal.新西兰的肿瘤学药物资助：一种不同的方法及一项提议。
J Oncol Pract. 2015 May;11(3):249-51. doi: 10.1200/JOP.2014.000083. Epub 2015 Mar 31.
5
Accelerated approval of oncology products: the food and drug administration experience.肿瘤学产品的加速审批：美国食品和药物管理局的经验。
J Natl Cancer Inst. 2011 Apr 20;103(8):636-44. doi: 10.1093/jnci/djr062. Epub 2011 Mar 21.
6
Informing prospective research subjects of the influence of regulatory requirements for drug approval on the design of clinical trials in oncology.向未来的研究对象告知药品审批监管要求对肿瘤学临床试验设计的影响。
Cancer. 2007 Mar 15;109(6):1003-6. doi: 10.1002/cncr.22491.
7
Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies.肿瘤药物审批：在突破性治疗时代评估终点和证据。
Oncologist. 2017 Jul;22(7):762-767. doi: 10.1634/theoncologist.2017-0152. Epub 2017 Jun 2.
8
Regarding "Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies".关于“肿瘤药物审批：在突破性疗法时代评估终点和证据”。
Oncologist. 2017 Jul;22(7):757-758. doi: 10.1634/theoncologist.2017-0202. Epub 2017 Jun 2.
9
A window into new drug development for urologic oncology. Part I: How bench-to-bedside research can result in approval.泌尿肿瘤学新药研发的视角。第一部分：从实验室到临床的研究如何促成获批。
Urol Oncol. 2015 Mar;33(3):115. doi: 10.1016/j.urolonc.2014.12.004. Epub 2015 Jan 22.
10
Academic training pathways in pediatric hematology-oncology.儿科血液肿瘤学的学术培训途径。
Pediatr Blood Cancer. 2006 Sep;47(3):239-41. doi: 10.1002/pbc.20671.

引用本文的文献

1
Putting the substance in substantial evidence: an evidence-based approach to flexible drug regulation.将该物质置于充分证据之中：一种基于证据的灵活药物监管方法。
Front Med (Lausanne). 2025 Mar 20;12:1337890. doi: 10.3389/fmed.2025.1337890. eCollection 2025.
2
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab.肿瘤学中加速批准途径的应用：帕博利珠单抗的案例研究
Drugs. 2024 Dec;84(12):1579-1601. doi: 10.1007/s40265-024-02111-7. Epub 2024 Nov 13.
3
National Comprehensive Cancer Network Guideline Recommendations of Cancer Drugs With Accelerated Approval.
国家综合癌症网络指南推荐加速批准的癌症药物。
JAMA Netw Open. 2023 Nov 1;6(11):e2343285. doi: 10.1001/jamanetworkopen.2023.43285.
4
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.药物研发的特殊 FDA 认定：孤儿药、快速通道、加速批准、优先审评和突破性疗法。
Eur J Health Econ. 2024 Aug;25(6):979-997. doi: 10.1007/s10198-023-01639-x. Epub 2023 Nov 14.
5
The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints.免疫治疗时代肝细胞癌放射学反应评估的演变情况：替代终点的优势与不足
Biomedicines. 2022 Nov 6;10(11):2827. doi: 10.3390/biomedicines10112827.
6
Conditional Drug Approval as a Path to Market for Oncology Drugs in Canada: Challenges and Recommendations for Assessing Eligibility and Regulatory Responsiveness.加拿大肿瘤药物的有条件药物批准上市途径：评估资格和监管响应性的挑战与建议
Front Med (Lausanne). 2022 Feb 3;8:818647. doi: 10.3389/fmed.2021.818647. eCollection 2021.
7
Pre-approval and post-approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs.在欧洲，有条件批准的癌症药物的证据和临床获益的审批前和审批后可及性：与标准批准的癌症药物的比较。
Br J Clin Pharmacol. 2022 May;88(5):2169-2179. doi: 10.1111/bcp.15141. Epub 2022 Jan 5.
8
Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study.加速批准癌症药物阴性确证性试验的监管和临床后果：回顾性观察研究。
BMJ. 2021 Sep 8;374:n1959. doi: 10.1136/bmj.n1959.
9
Perspectives in the study of the political economy of COVID-19 vaccine regulation.新冠疫苗监管的政治经济学研究视角
Regul Gov. 2021 May 24. doi: 10.1111/rego.12413.
10
Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe.不确定性下的决策：比较美国和欧洲药品的监管审查与卫生技术评估审查
Clin Pharmacol Ther. 2020 Aug;108(2):350-357. doi: 10.1002/cpt.1835. Epub 2020 Apr 20.